Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of QAX576 against asthma attacks in adults with moderate persistent allergic asthma

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis

Criteria

Inclusion Criteria:

• History of asthma attacks

• Taking inhaled corticosteroids

• Non-smoking

Exclusion Criteria:

• Women of child-bearing potential

• History of respiratory disease other than asthma

• History of severe allergy to food or drugs

• Previous use of monoclonal antibodies

• Very low or high body weight

Other protocol-defined inclusion/exclusion criteria may apply.